EDITAS MEDICINE INC (EDIT) Stock Analyst Ratings
USA - NASDAQ:EDIT - US28106W1036 - Common Stock
2.61 USD
+0.09 (+3.57%)
ChartMill assigns a Buy % Consensus number of 73% to EDIT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.03. This target is 54.37% above the current price.
EDIT was analyzed by 20 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about EDIT.
In the previous month the buy percentage consensus was at a similar level.
EDIT was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-03 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-13 | Baird | Maintains | Outperform -> Outperform |
| 2025-05-13 | Baird | Maintains | Outperform -> Outperform |
| 2025-04-28 | HC Wainwright & Co. | Initiate | Buy |
| 2024-12-16 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-12-16 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2024-12-13 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2024-12-13 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-12-13 | Stifel | Downgrade | Buy -> Hold |
| 2024-12-13 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-12-13 | Baird | Maintains | Outperform -> Outperform |
| 2024-12-11 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-11-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-05 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-11-05 | Stifel | Maintains | Buy -> Buy |
| 2024-11-05 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-11-05 | Truist Securities | Maintains | Buy -> Buy |
| 2024-10-23 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-10-23 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2024-10-22 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-09-19 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-09-17 | Jones Trading | Initiate | Buy |
| 2024-08-08 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-08-08 | Truist Securities | Maintains | Buy -> Buy |
| 2024-08-08 | B of A Securities | Upgrade | Neutral -> Buy |
| 2024-06-18 | Oppenheimer | Maintains | Perform -> Perform |
| 2024-05-30 | Evercore ISI Group | Maintains | In-Line -> In-Line |
EDITAS MEDICINE INC / EDIT FAQ
What do analysts expect the price target to be for EDITAS MEDICINE INC (EDIT)?
20 analysts have analysed EDIT and the average price target is 4.03 USD. This implies a price increase of 54.37% is expected in the next year compared to the current price of 2.61.
What is the consensus rating for EDITAS MEDICINE INC (EDIT) stock?
The consensus rating for EDITAS MEDICINE INC (EDIT) is 73 / 100 . This indicates that analysts generally have a positive outlook on the stock.